Multimodality and molecular imaging of matrix metalloproteinase activation in calcific aortic valve disease

Journal of Nuclear Medicine

Volumn 56, Issue 6, 2015, Pages 933-938

  Jung, Jae Joon ^a,b   Razavian, Mahmoud ^a,b   Challa, Azariyas A ^a,b   Nie, Lei ^a,b   Golestani, Reza ^a,b   Zhang, Jiasheng ^a,b   Ye, Yunpeng ^a,b   Russell, Kerry S ^a   Robinson, Simon P ^c   Heistad, Donald D ^d   Sadeghi, Mehran M ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c Lantheus Medical Imaging   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

Aortic valve; Calcification; Inflammation; Matrix metalloproteinases; Molecular imaging

Indexed keywords

APOLIPOPROTEIN E; CD68 ANTIGEN; MATRIX METALLOPROTEINASE; RADIOPHARMACEUTICAL AGENT; RP 805 TC 99M; UNCLASSIFIED DRUG; TECHNETIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA FLOW; AORTA VALVE DISEASE; ARTICLE; BLOOD FLOW VELOCITY; CALCIFIC AORTIC VALVE DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; FEASIBILITY STUDY; HISTOPATHOLOGY; HYPERLIPOPROTEINEMIA TYPE 3; MOLECULAR IMAGING; MOUSE; MURINE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASCULAR REMODELING; WESTERN DIET; WILD TYPE MOUSE; ZYMOGRAPHY; ANIMAL; AORTA VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; CHEMISTRY; ENZYMOLOGY; GENETICS; HEART DEFECTS, CONGENITAL; HEART VALVE DISEASES; HUMAN; LIPID DIET; METABOLISM; MULTIMODAL IMAGING; PATHOLOGY; SCINTISCANNING; TRANSGENIC MOUSE;

ANIMALS; AORTIC VALVE; AORTIC VALVE STENOSIS; APOLIPOPROTEINS E; CALCINOSIS; DIET, HIGH-FAT; ECHOCARDIOGRAPHY; HEART DEFECTS, CONGENITAL; HEART VALVE DISEASES; HUMANS; MATRIX METALLOPROTEINASES; MICE; MICE, TRANSGENIC; MOLECULAR IMAGING; MULTIMODAL IMAGING; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84930359029     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.152355     Document Type: Article

References (29)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics: 2011 update-a report from the American Heart Association. Circulation. 2011;123:e18-e209.
2. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipidlowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389-2397.
3. RossebÁ AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359: 1343-1356.
4. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial. Circulation. 2010;121:306-314.
5. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease: cardiovascular health study. J Am Coll Cardiol. 1997;29:630-634.
6. Aikawa E, Nahrendorf M, Sosnovik D, et al. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation. 2007;115:377-386.
7. Aikawa E, Aikawa M, Libby P, et al. Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation. 2009;119:1785-1794.
8. Waters EA, Chen J, Allen JS, Zhang H, Lanza GM, Wickline SA. Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. J Cardiovasc Magn Reson. 2008;10:43.
9. Marincheva-Savcheva G, Subramanian S, Qadir S, et al. Imaging of the aortic valve using fluorodeoxyglucose positron emission tomography increased valvular fluorodeoxyglucose uptake in aortic stenosis. J Am Coll Cardiol. 2011;57:2507-2515.
10. Dweck MR, Jones C, Joshi NV, et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation. 2012;125:76-86.
11. Bossé Y, Miqdad A, Fournier D, Pepin A, Pibarot P, Mathieu P. Refining molecular pathways leading to calcific aortic valve stenosis by studying gene expression profile of normal and calcified stenotic human aortic valves. Circ Cardiovasc Genet. 2009;2:489-498.
12. Su H, Spinale FG, Dobrucki LW, et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation. 2005;112:3157-3167.
13. Zhang J, Nie L, Razavian M, et al. Molecular imaging of activated matrix metalloproteinases in vascular remodeling. Circulation. 2008;118:1953-1960.
14. Razavian M, Zhang J, Nie L, et al. Molecular imaging of matrix metalloproteinase activation to predict murine aneurysm expansion in vivo. J Nucl Med. 2010;51:1107-1115.
15. Razavian M, Nie L, Challa A, et al. Lipid lowering and imaging protease activation in atherosclerosis. J Nucl Cardiol. 2014;21:319-328.
16. Miller JD, Weiss RM, Heistad DD. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res. 2011;108:1392-1412.
17. Akat K, Borggrefe M, Kaden JJ. Aortic valve calcification: basic science to clinical practice. Heart. 2009;95:616-623.
18. Chen JH, Simmons CA. Cell-matrix interactions in the pathobiology of calcific aortic valve disease: critical roles for matricellular, matricrine, and matrix mechanics cues. Circ Res. 2011;108:1510-1524.
19. Helske S, Kupari M, Lindstedt KA, Kovanen PT. Aortic valve stenosis: an active atheroinflammatory process. Curr Opin Lipidol. 2007;18:483-491.
20. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 2011;278:28-45.
21. Koppisetti RK, Fulcher YG, Jurkevich A, et al. Ambidextrous binding of cell and membrane bilayers by soluble matrix metalloproteinase-12. Nat Commun. 2014;5:5552.
22. Edep ME, Shirani J, Wolf P, Brown DL. Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc Pathol. 2000;9:281-286.
23. Satta J, Oiva J, Salo T, et al. Evidence for an altered balance between matrix metalloproteinase-9 and its inhibitors in calcific aortic stenosis. Ann Thorac Surg. 2003;76:681-688.
24. Fondard O, Detaint D, Iung B, et al. Extracellular matrix remodelling in human aortic valve disease: The role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J. 2005;26:1333-1341.
25. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res. 2002;90:251-262.
26. Hakuno D, Kimura N, Yoshioka M, et al. Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents. J Clin Invest. 2010;120:2292-2306.
27. Clark-Greuel JN, Connolly JM, Sorichillo E, et al. Transforming growth factorbeta1 mechanisms in aortic valve calcification: increased alkaline phosphatase and related events. Ann Thorac Surg. 2007;83:946-953.
28. Kaden JJ, Dempfle CE, Kilic R, et al. Influence of receptor activator of nuclear factor kappa B on human aortic valve myofibroblasts. Exp Mol Pathol. 2005;78:36-40.
29. Balachandran K, Sucosky P, Jo H, Yoganathan AP. Elevated cyclic stretch alters matrix remodeling in aortic valve cusps: implications for degenerative aortic valve disease. Am J Physiol Heart Circ Physiol. 2009;296:H756-H764.